Featured Research

from universities, journals, and other organizations

Prostate cancer drug shows promise in triple-negative and estrogen-positive breast cancer

Date:
December 3, 2012
Source:
University of Colorado Denver
Summary:
Long known to drive prostate cancer, androgen receptors are a new target in breast cancer treatment. This week, a promising clinical trial at the University of Colorado Cancer Center flips from Phase I (proving safety) to Phase II (proving effectiveness).

Breast cancers are defined by their drivers -- estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options -- this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative. A decade ago, work at the University of Colorado Cancer Center added another potential driver to the list -- the androgen receptor -- and this week marks a major milestone in a clinical trial targeting this cause of breast cancer growth.

Related Articles


In fact, 75 percent of all breast cancers and about 20 percent of triple negative cancers are positive for the androgen receptor. Blocking the androgen receptor may stop the growth of some triple negative breast cancers -- these aggressive cancers for which chemotherapy, radiation, surgery and hope have long been the only treatments.

"This work is a concise example of modern cancer science in action. We noticed something in the clinic, worked on it in the lab, and now are happy to report the lab work is once again back in the clinic where it has the very real potential to benefit patients," says Anthony Elias, MD, breast cancer program director at CU Cancer Center.

The work started in 2001 when Elias took the clinical observation of estrogen-positive breast cancers that responded poorly or only very temporarily to estrogen-blocking treatments, to colleague Jennifer Richer, PhD, co-director of the CU Cancer Center Tissue Processing and Procurement Core. In these cases, something else was driving the cancer. What was the pathway? Richer showed that it was the androgen receptor.

Androgens including testosterone have long been implicated as a driver of prostate cancer and so drugs targeting both the body's production of androgens and cancer cells' ability to use the hormone were already in the development pipeline. Richer started with cell culture and animal model work on a then-experimental drug by the company Medivation known as MDV-3100.

"Normally, the way these hormones work is by attaching to receptors in the cell cytoplasm, at which point the receptor draws itself and the hormone molecule inside the nucleus where it regulates genes," Richer says. The genes regulated by these hormones tell breast cancer cells to survive and reproduce beyond control. The drug MDV-3100, now known as Enzalutamide, which recently gained FDA approval for use with prostate cancer, makes androgen receptors unable to go into a cell's nucleus -- and so the message of growth never gets delivered.

"Interestingly, it seems that estrogen-positive breast cancers are susceptible to the same drug," Richer says, explaining that something about the way the signal of estrogen is transmitted inside a cell's nucleus requires the (counterintuitive) presence of androgen receptors in the nucleus, too.

And so Enzalutamide has many potential uses in the treatment of breast cancer: as a first-line drug against androgen receptor-positive cancers with or without additional hormonal drivers, as a second-line drug against tumors that have mutated away from estrogen- or HER2-dependence by adopting androgen-dependence, in combination with drugs that target these other hormones to disallow cancer from mutating toward androgen-dependence in the first place, or perhaps in addition to or instead of existing treatments for estrogen-positive breast cancers -- which seem susceptible to this anti-androgen therapy.

This week, after seeing, "no additional toxicities," Elias expects an ongoing Phase I clinical trial of Enzalutamide for triple-negative breast cancers to flip to a Phase II trial -- from proving safety to demonstrating results. In addition to the CU Cancer Center, the trial is being offered at Memorial Sloan-Kettering Cancer Center and the Karmanos Cancer Institute. Richer and Elias will present additional findings from their work with androgen-positive breast cancer at the San Antonio Breast Cancer Symposium in December and will hear about a major invited grant proposal to the U.S. Department of Defense the same month.

"It's an exciting time for breast cancer research," Elias says. "We should know soon if we have a viable new target in breast cancer treatment."

Along with validating a new target, Richer and Elias may soon provide a powerful new treatment for breast cancers that evade current therapies.


Story Source:

The above story is based on materials provided by University of Colorado Denver. Note: Materials may be edited for content and length.


Cite This Page:

University of Colorado Denver. "Prostate cancer drug shows promise in triple-negative and estrogen-positive breast cancer." ScienceDaily. ScienceDaily, 3 December 2012. <www.sciencedaily.com/releases/2012/12/121203121640.htm>.
University of Colorado Denver. (2012, December 3). Prostate cancer drug shows promise in triple-negative and estrogen-positive breast cancer. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2012/12/121203121640.htm
University of Colorado Denver. "Prostate cancer drug shows promise in triple-negative and estrogen-positive breast cancer." ScienceDaily. www.sciencedaily.com/releases/2012/12/121203121640.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Christmas Kissing Good for Health

Christmas Kissing Good for Health

Reuters - Innovations Video Online (Dec. 22, 2014) Scientists in Amsterdam say couples transfer tens of millions of microbes when they kiss, encouraging healthy exposure to bacteria. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Brain-Dwelling Tapeworm Reveals Genetic Secrets

Brain-Dwelling Tapeworm Reveals Genetic Secrets

Reuters - Innovations Video Online (Dec. 22, 2014) Cambridge scientists have unravelled the genetic code of a rare tapeworm that lived inside a patient's brain for at least four year. Researchers hope it will present new opportunities to diagnose and treat this invasive parasite. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins